30 Nov

Melanoma: BMY’s Growing Opportunity in Fiscal 2018

WRITTEN BY Margaret Patrick

Melanoma revenue contribution

In Bristol-Myers Squibb’s (BMYthird-quarter earnings conference call, the company estimated the contribution of melanoma indication to Opdivo’s US market revenues to be close to 30%. The contribution is ~20% in ex-US markets. The company expects the contribution of lung cancer indication to Opdivo’s revenues in ex-US markets to gradually decline as the drug penetrates deeper into other newly launched indications.

Melanoma: BMY’s Growing Opportunity in Fiscal 2018

Growth drivers

On December 20, 2017, Bristol-Myers Squibb issued a press release announcing FDA approval of Opdivo in adjuvant melanoma indication. According to Bristol-Myers Squibb’s Evercore ISI HealthCONx Conference transcript, the company has witnessed rapid adoption of the drug in the US market with rising patient treatment rates in the adjuvant melanoma setting. According to Bristol-Myers Squibb, the company accounts for 70% of the market share in adjuvant melanoma indication in the United States.

On July 31, Bristol-Myers Squibb issued a press release announcing European Commission approval of Opdivo in adjuvant melanoma indication. Opdivo was launched in Europe in adjuvant melanoma indication in September. The company is focused on securing reimbursement on a per market basis. According to the company’s third-quarter earnings conference call, the uptake of Opdivo for adjuvant melanoma in Germany is progressing at a rate similar to the rate witnessed in the United States and in line with Bristol-Myers Squibb’s expectations.

According to Bristol-Myers Squibb’s third-quarter earnings conference call, data from CheckMate-511 evaluating two safety profiles of different dosages of the Opdivo and Yervoy combination regimen in melanoma indication might provide physicians with higher optionality and flexibility while treating patients.

Next, we’ll discuss growth trends for Bristol-Myers Squibb in the renal cell carcinoma market.

Latest articles

On June 25, the soft economic data isn't an isolated case. We have been getting a flurry of dismal data points. The US economy added only 75,000 non-farm jobs in May.

French retail giant Carrefour has agreed to sell an 80% stake in its China operations for ~$705 million to Suning.com, an Alibaba (BABA) backed company. While China represents a massive opportunity with its almost 1.4 billion population, it has not been an easy market for foreign companies, at least when it comes to retail and e-commerce.

On June 25, US Secretary of Agriculture Sonny Perdue told CNN in an interview that the US-China trade war has impacted US farmers. He said that farmers “are one of the casualties” of the trade war.

25 Jun

Hang Seng and Nikkei 225 Lose amid Trade Worries

WRITTEN BY Mayur Sontakke, CFA, FRM

After rising marginally yesterday, Hong Kong’s Hang Seng Index fell today. The index lost 1.15% to end at 28,185.98. Only seven stocks in the index rose, while 39 declined. Four remained unchanged. Tencent Holdings (TCEHY) was one of the worst performers with a 1.8% fall.

Square (SQ) was absent from the list of the inaugural members of the Libra Association, the entity that will ensure that Facebook’s (FB) Libra cryptocurrency works as intended. Nearly 30 companies have joined the Libra Association.

Kroger (KR) stock fell 2.2% on June 20—the day the company announced its results for the first quarter, which ended on May 25. The negative sentiment for the stock continued.